Pyxis Oncology Bets on Refined Cancer Drug and New Leadership

BOSTON, MA – March 23, 2026 – Pyxis Oncology is navigating a pivotal year, advancing its lead cancer drug candidate while installing new leadership and managing a finite cash runway. In a comprehensive business update, the clinical-stage company announced it has completed enrollment for a key study of its drug, micvotabart pelidotin (MICVO), and is refining its dosing strategy to improve patient safety, a crucial step as it prepares for a series of high-stakes data releases in 2026.

The Boston-based firm also reported its fourth-quarter and full-year 2025 financial results, outlining a path forward under the new leadership of Interim CEO Thomas Civik, an industry veteran with a history of steering biotech companies to successful outcomes. With its cash expected to last into the fourth quarter of this year, the company is laser-focused on delivering results that could validate MICVO's potential in treating difficult head and neck cancers.

A Safer Path for a Difficult Cancer?

The centerpiece of Pyxis Oncology's strategy is MICVO, a novel antibody-drug conjugate (ADC) being tested in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), a disease with significant unmet medical need. The company has now completed target enrollment in its Phase 1 monotherapy dose expansion study, a key milestone that sets the stage for an updated data readout by mid-2026.

Preliminary data shared in December 2025 sparked investor interest, showing a 46% confirmed objective response rate (ORR) in 13 evaluable patients receiving MICVO as a standalone therapy. The results were even more pronounced when combined with Merck’s blockbuster immunotherapy, KEYTRUDA®, showing a 71% ORR in a small group of seven patients.

While promising, the initial study also revealed a common challenge with powerful ADCs: managing toxicity. Treatment-related adverse events were more frequent and led to discontinuations exclusively in patients with higher body weight. In response, Pyxis has proactively implemented a modified weight-based dosing approach, including dose capping and using an "adjusted ideal body weight" (AIBW) calculation. This strategy is designed to optimize drug exposure across all patients, aiming to reduce side effects without compromising the drug's cancer-killing efficacy. This type of dose optimization is becoming a standard practice in the ADC field to widen the therapeutic window, and its successful implementation will be a key focus of the upcoming data release.

“We are laser focused on clinical execution and operations so that we can deliver a robust dataset in mid-2026 that will allow us to further assess the potential of MICVO as monotherapy,” said Thomas Civik, Interim Chief Executive Officer. He noted the company will specifically assess whether the dosing modification achieved its intended goals of improving the benefit-risk profile.

Adding to the company's momentum, Pyxis announced it has already received feedback and alignment from the U.S. Food and Drug Administration (FDA) on the design for a future pivotal trial, a critical step that helps de-risk the regulatory path forward.

New Captain at the Helm Amid Financial Headwinds

The clinical advancements are backdropped by significant corporate changes. In February 2026, the company appointed Thomas Civik as Interim CEO. Civik, a board member since 2021, brings a formidable track record. He most notably served as CEO of Five Prime Therapeutics, which he led to a $1.9 billion acquisition by Amgen in 2021. His experience in oncology at Genentech and in commercial strategy at Foundation Medicine provides a steady hand as Pyxis navigates its most critical period.

Civik's appointment is part of a broader leadership build-out, with recent hires including Heather Knowles as Head of Global Clinical Operations and Brian Freeman as Global Program Leader for MICVO, both bringing extensive experience from companies like Moderna and ImmunoGen.

This bolstered leadership team will need its expertise to manage the company's financial position. Pyxis ended 2025 with $68.3 million in cash, cash equivalents, and short-term investments, which it projects will fund operations into the fourth quarter of 2026. This runway puts pressure on the company to deliver positive results in its upcoming data readouts to secure future funding or partnerships.

The company's financial filings show a net loss of $79.6 million for 2025, with research and development expenses rising to $73.7 million as the MICVO trials accelerated. To extend its runway, Pyxis has employed non-dilutive funding strategies, including the sale of royalty rights for a separate drug, Enzeshu®, for an $11 million upfront payment. While analysts note the company has more cash than debt, the burn rate is a point of concern, making the upcoming clinical milestones all the more crucial for building investor confidence.

Positioning MICVO in the Competitive ADC Arena

Pyxis is betting that MICVO's unique design can help it stand out in the increasingly crowded and highly competitive field of antibody-drug conjugates. Unlike many ADCs that target proteins on the surface of cancer cells, MICVO targets a protein called EDB+FN, which is part of the non-cellular structure, or extracellular matrix, that surrounds and supports tumors. This target is abundant in many solid tumors but largely absent from healthy adult tissues, potentially allowing for more precise tumor targeting.

The drug is designed to fight cancer through a three-pronged attack: directly killing tumor cells, a "bystander effect" that kills nearby cancer cells that may not have the target, and by triggering immunogenic cell death, which helps stimulate the patient's own immune system to fight the cancer. This mechanism provides a strong scientific rationale for combining MICVO with immunotherapies like KEYTRUDA®, a strategy the company is actively pursuing with encouraging early results.

The company continues to build the scientific case for its lead asset, with new preclinical data slated for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in April. This research further explores MICVO's ability to modulate the tumor's immune landscape, strengthening the argument for its combination therapy approach.

With target enrollment complete and two major data updates on the horizon for 2026—monotherapy data mid-year and combination data in the second half—Pyxis Oncology is at a critical inflection point. The company has assembled an experienced team and refined its clinical strategy. Now, patients, physicians, and investors are waiting to see if the upcoming data will confirm that MICVO can deliver on its considerable promise for patients battling a devastating form of cancer.